The primary objective was to evaluate the significance of cfDNA‐based analyses for assessing malignancy risk—particularly through the detection of KRAS and GNAS mutations—and to explore the role of CECs in enhancing clinical decision‐making strategies for IPMN treatment. Here, GNAS is linked to pancreatic intraductal papillary-mucinous neoplasm.